Daily Journal Staff Writer
Anaheim-based pharmaceutical developer Questcor Pharmaceuticals Inc. tapped Latham & Watkins LLP for counsel in its $5.6 billion sale to drugmaker Mallinckrodt Pharmaceuticals PLC, a deal announced Monday.
The combination is expected to expand Mallinckrodt's offering of specialty pharmaceuticals. Questcor's flagship drug, Acthar, is used to treat inflammatory conditions and autoimmune...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In